← Russell 3000 cross-section

LCTX Lineage Cell Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$292m
Revenue TTM
$13m
Net income TTM
$-32m
Free cash flow
$-24m
Composite score
42.2
Sector rank
#2676

Valuation

P / E
EV / EBITDA
EV / sales
18.4
FCF yield
-8.35%
Earnings yield vs 10-yr
-15.79pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-246.6%
EBITDA margin
ROE
-53.0%
ROIC
-266.2%
Revenue growth
19.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The remaining decrease was largely comprised of approximately $0.7 million related to deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc., in the second quarter of 2025, partially offset by a $0.3 million increase in collaboration revenues related to our research collaboration agreement with WDI. For the six months ended June 30, 2026, the $1.5 million decrease in total revenues as compared to the prior year was primarily attributable to a $1.3 million decrease in collaboration revenues and a decrease of approximately $0.2 million in royalty revenue. …Lineage Cell Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →